The Home Consortium Ltd (ASX: HMC) share price was in focus after announcing acquisitions and investments for HealthCo.
HealthCo Updates
Acquisition
It was announced that HealthCo was acquiring eight private oncology assets with triple-net leases from GenesisCare for $110.3 million.
This acquisition will be done through a sale and leaseback with GenesisCare, one of the largest independent providers of integrated oncology services with over 440 clinics internationally, including 370 therapy treatment centres in Australia, the USA, the UK and Spain.
These assets comes with a weighted average passing yield of approximately 4.5%. The weighted average lease expiry (WALE) is 10.7 years, with long term options across all properties. HealthCo said that there is “strong” embedded rental growth and inflation protection.
GenesisCare will continue to operate each centre and there will be no impact on patient care.
Partnership
HealthCo has agreed to partner with Acurio to initially develop a 78 bed integrated private hospital which will be leased to Acurio under a 15-year lease. In addition, the joint venture will develop an integrated health and innovation precinct with a potential end value of more than $500 million.
For the first stage HomeCo has agreed terms to fund at least $70 million of capital expenditure and construction is expected to commence by October 2021.
HealthCo capital raising update
The previously proposed strategy was to establish an ASX-listed HealthCo and Unlisted HealthCo by the end of 2021. This remains on track.
The initial public offering process for an ASX-listed HealthCo which will look to raise at least $500 million of equity has commenced and is on track for a listing in the first half of FY22.
An unlisted HealthCo is also on-track for establishment with a target equity raise of $1 billion and initial first close of at least $500 million by the end of 2021.
HomeCo guidance
At the end of the HealthCo update, it reaffirmed its FY21 FFO guidance of no less than $35 million, or 12.9 cents per share. It also reaffirmed its FY21 dividend guidance of 12 cents per share.
